ABSTRACT

Obstructive sleep apnoea and chronic obstructive pulmonary disease (COPD), each a prevalent and clinically important condition in adults, carry numerous common risk factors, including obesity and smoking. It is estimated that the coexistence of obstructive sleep apnoea and COPD, the COPD/obstructive sleep apnoea overlap syndrome, affects more than 1% of the general population. The presence of such overlap, when obstructive sleep apnoea is untreated, carries a risk of more adverse diurnal and nocturnal physiological and clinical outcomes, including greater sleep fragmentation, more severe nocturnal hypoxaemia, and increased overall mortality than is documented for COPD alone and obstructive sleep apnoea alone. Effective identification and treatment of the comorbid obstructive sleep apnoea and the other features of sleep-disordered breathing in the COPD/obstructive sleep apnoea overlap syndrome improve overall clinical outcomes in the condition. (BRN Rev. 2017;3:30-41)

Corresponding author: José M. Marin, jmmarint@unizar.es

Key words: Chronic obstructive pulmonary disease. Obstructive sleep apnoea. Overlap syndrome.
INTRODUCTION

The coexistence of chronic obstructive pulmonary disease (COPD) and obstructive sleep apnoea (OSA) was first described as the “overlap syndrome” by David Flenley almost 30 years ago. He pointed out that polysomnography should be considered in COPD patients with obesity, snoring, or morning headache associated with nocturnal oxygen therapy to assess for the presence of associated OSA. At the present time, the term “overlap syndrome” is not a formal diagnostic designation for patients suffering from OSA and COPD.

In normal subjects, sleep is associated with adaptive changes of the airways, lungs, and chest wall mechanics. In patients with COPD, such physiological changes, as well as the pathophysiological changes of sleep-breathing disorders such as OSA, may result in acute and chronic adverse effects, including precipitation or worsening of hypoxaemia, hypercapnia, and reduced airflow, which in the long-term can contribute to worse outcomes in these chronic pulmonary disorders. The clinical relevance of identifying the coexistence of a primary sleep disorder such as OSA in patients with COPD lies not only in the diagnosis of an overlap syndrome; it also involves a worse prognosis for these coexisting respiratory diseases and the need for specific treatment of the concomitant sleep-disordered breathing. This update focuses on the physiology of sleep disturbances in COPD as well as the clinical implications of OSA in COPD.

SLEEP IN COPD

In COPD patients, sleep is associated with reduced ribcage contribution to breathing, diaphragmatic inefficiency, and increased accessory muscle contribution to breathing. The result is a reduction in functional residual capacity, which may augment ventilation-perfusion V̇A/Q mismatching and hypoxaemia. More than 50% of COPD patients with daytime arterial oxygen saturation of haemoglobin (SaO₂) > 90% breathing ambient air, and without concomitant OSA, experience significant oxygen desaturation during sleep, defined as spending at least 30% of the night with SaO₂ < 90%. Daytime gas exchange abnormalities are, however, somewhat predictive of sleep oxygen desaturation among COPD patients. Accentuated physiological hypoventilation in COPD is also the consequence of decreased central respiratory drive response to chemical and mechanical inputs, increased upper airway resistance due to a loss of tone in the upper pharyngeal muscles, and reduced efficiency of diaphragmatic contraction due to lung hyperinflation. The consequences of nocturnal hypoxaemia and hypercapnia are well known and include arrhythmias and pulmonary hypertension. In addition, recent data suggest that disturbed sleep is an independent risk factor of COPD exacerbations and mortality. Sleep disturbance is very common in COPD without other coexistent primary sleep disorders. In a large survey done in North America and Europe, 40% of patients reported problems with their sleep. In a recent European survey, 78.1% of patients with COPD reported some degree of night time symptoms, including one or more of the following: dyspnoea, cough with increased sputum production, wheezing, and difficulty with maintenance of sleep. The prevalence of such night time symptoms was positively correlated with the severity of spirometrically measured airflow obstruction. Polysonmography studies have shown that these
OBSTRUCTIVE SLEEP APNOEA-COPD OVERLAP SYNDROME

Prevalence

There are no studies that directly assess the prevalence of the overlap syndrome. Since COPD and OSA are each increasing throughout the world in association with an aging population, presumably the overlap syndrome is also becoming more prevalent. It is estimated that 10% of the general population has COPD as defined as a forced expiratory volume in one second/forced vital capacity (FEV1/FVC) < 0.7 ratio and FEV1 < 80% predicted. The prevalence of COPD increases with age and is directly related to the prevalence of tobacco smoking as a major COPD risk factor. Among men and women between the ages 30 and 60, 20 and 9%, respectively, had an apnoea-hypopnoea index (AHI) of at least five events/hour in the Wisconsin Sleep Cohort Study. Since this report was published 20 years ago, data from the same on-going cohort provide prevalence estimates of moderate to severe sleep-disordered breathing (SDB) of the sleep apnoea type (AHI ≥ 15 events/hour), thus showing a substantial increase over the last two decades. The sex disparity of OSA ends around age 55, with a sharp rise among postmenopausal women.

In clinical series, it has been noted that 11% of patients with OSA, as defined by an apnoea plus hypopnoea index > 20/hour, have airflow limitation on spirometry. In a European population study of patients with predominantly mild COPD, the coincidence of OSA syndrome (AHI > 5/hour accompanied by excessive daytime sleepiness) occurred in 1% of the total population. The Sleep Heart Health Study, a community-based cohort study that included 5,954 participants who had polysomnography and spirometry at baseline, found that 19% had airway obstruction (defined as FEV1/FVC < 0.7). The prevalence of OSA, defined as a respiratory disturbance index > 10 events/hour, was not greater in subjects with airway obstruction (defined as FEV1/FVC < 0.7) compared with the non-obstructed population. There were 254 participants (4.3%) who had both characteristics: obstructive airways disease and sleep apnoea. As expected, the respiratory disturbance index increased with higher body mass index (BMI) in participants with and without airway limitation. The age effect was not specifically addressed in this study. In short, the few available population studies regarding the association between COPD and OSA (i.e. overlap syndrome) show great variability in the prevalence of this association. It does appear that the world’s adult population is affected in a range between 1 and 4%. This range likely reflects, at least to some extent, differences in the criteria used to define OSA and the age and weight of the subjects studied.

Risk factors

Age and increase weight are the main risk factors for OSA in the general population. Patients with COPD can incur in specific OSA risks, including obesity irrespective of airflow
obstruction severity\textsuperscript{21}, active smoking\textsuperscript{22,23}, and both pharyngeal and lower extremity oedema associated with episodic use of oral corticosteroids and impaired cardiac output\textsuperscript{24}. There is also evidence that patients with advanced COPD who lose weight may show reduced diathesis for upper airway obstruction (Fig. 1).

**Pathophysiology**

Patients with COPD/OSA overlap syndrome had a lower total sleep time, lower sleep efficiency, and higher daytime sleepiness than patients with COPD alone. They were also more likely to have greater sleep-related oxygen desaturation compared with participants with OSA or airway obstruction alone\textsuperscript{20}. Further, respiratory control centre output is reduced during sleep, especially during REM sleep\textsuperscript{25}, including blunted ventilatory responses and mouth occlusion pressure responses to carbon dioxide (CO\textsubscript{2})\textsuperscript{26}. Respiratory mechanics are deeply affected during sleep in patients with overlap at three main levels: upper and lower airway, thoracic ribcage, and central respiratory control (Fig. 2).

**Figure 1.** Interactions between COPD and obstructive sleep apnoea.

OSA: obstructive sleep apnoea.

**Figure 2.** Pathways involved in producing nocturnal hypoxaemia and hypercapnia in overlap syndrome.

CO\textsubscript{2}: carbon dioxide; OSA: obstructive sleep apnoea; V\textsubscript{A}/Q: ventilation/perfusion.
**Upper and lower airway**

Obstructive sleep apnoea is classically associated with increased upper airway resistance. During sleep, especially when supine, the base of the tongue and the soft palate approximate the posterior wall of the pharynx, resulting in anterior-posterior narrowing. In addition, due to negative intraluminal pressure during inspiration and a reduction in pharyngeal dilator muscle tone, lateral pharyngeal wall intrusion occurs, resulting in airway collapse. In active smokers with OSA, local mucosal inflammation may contribute to this phenomenon. COPD is characterized by increased lower airway resistance due to bronchoconstriction, low elastic recoil, and excess airway secretions. During sleep, in COPD patients, two additional phenomena contribute to increases in airway resistance: the normal circadian change in airway calibre is followed by bronchoconstriction and cough reflex is reduced. Thus, accumulation of airway secretions leads to mucous plugging and a reduction in alveolar ventilation and VA/Q mismatching.

**Respiratory mechanics**

Sleep is associated with reduction in minute ventilation and functional residual capacity. This phenomenon is more profound within rapid eye movement (REM) sleep and increases partial pressure of CO₂ (PaCO₂) levels by 2-10 mmHg compared to daytime breathing. In COPD, a certain degree of gas trapping and hyperinflation is the rule. This is accompanied by a flattening of the diaphragm curvature that leads to its diminished excursion and the compensatory use of the accessory respiratory muscles. Together with sleep-related reduced tidal volume and ventilation, the final result is an increase in dead-space ventilation and reduction of alveolar ventilation. If COPD patients also have coexistent OSA, the apnoeic episodes further contribute to cause profound alveolar hypoventilation during sleep time.

**Control of breathing**

The central drive to breathe depends on neurochemical response to changes in oxygen (O₂) and CO₂ levels. During sleep and especially during REM sleep, these responses are blunted, allowing for more profound hypoxia and hypercapnia than observed while awake. When COPD patients develop such obstructive apnoea episodes, the compensatory response of the respiratory centre is slower, apnoea is longer, and changes in partial pressure of oxygen (PaO₂) and PaCO₂ are more intense compared with non-COPD subjects. Patients with COPD/OSA overlap syndrome who have hypoxaemia when awake are especially prone to nocturnal oxygen desaturation by being on the steep portion of the oxyhaemoglobin dissociation curve.

**Clinical features in overlap syndrome**

Patients with overlap syndrome have a shorter total sleep time, lower sleep efficiency, and higher daytime sleepiness than patients with COPD alone. There are no symptoms or other clinical data that can differentiate between patients with COPD/OSA overlap and patients with OSA or COPD. Compared with patients with COPD alone or OSA alone,
overlap patients of similar ages tend to be more obese and to have more comorbid conditions. They also report more daytime sleepiness and poorer quality of life than either COPD or OSA patients without overlap syndrome.

Sleep recordings of patients with COPD/OSA overlap show a lower total sleep time, lower sleep efficiency, and greater sleep fragmentation than those with COPD or OSA alone. More severe nocturnal O₂ desaturation is also a characteristic feature in these patients compared with either condition alone. Subjects with OSA alone return to a normal SO₂ in sleep between obstructive events (i.e. intermittent hypoxaemia), whereas in COPD alone, as a result of the diathesis to sleep-related hypoventilation and ventilation-perfusion mismatch as noted before, nocturnal O₂ saturation characteristically decreases more evenly throughout sleep and at the termination of an obstructive episode tends not to return to the initial baseline level (Fig. 3). A typical patient with overlap syndrome has a reduced awake and asleep baseline SO₂, a lower mean sleep-related SO₂, and a longer time in hypoxaemia than patients with OSA or COPD alone.

The majority of patients with OSA alone do not develop significant sleep-related hypercapnia.
because of inter-apnoea hyperventilation. However, if the patient also has COPD, the abnormal mechanical and chemical ventilatory responses as noted before may result in post-apnoea CO₂ levels that do not return to baseline. Over time a progressive desensitization of the respiratory centre in response to OSA-related hypoxic-hypercapnic episodes develops, such that patients with COPD/OSA overlap syndrome can remain hypercapnic during sleep. Of note, continuous positive airway pressure (CPAP) treatment can partially reverse this phenomenon. Although daytime hypercapnia can develop in OSA without COPD, awake hypercapnia is much more frequent in the patient with overlap syndrome. Both daytime hypoxaemia and hypercapnia have been found to be predictors of right-sided heart failure in COPD patients, and therefore these should be considered potentially treatable markers of otherwise poorer prognosis in COPD/OSA overlap.

Excessive sleepiness in patients with OSA alone is associated with decrements in quality of life and work performance. Further, there is also a strong association between OSA severity, as measured by the AHI, and the risk of traffic accidents. Such consequences in overlap syndrome have not been evaluated specifically.

**Cardiovascular consequences**

Increased risk of cardiovascular morbidity and mortality has been associated with both OSA and COPD alone. Epidemiological data show a strong association between OSA and incident arterial hypertension. In COPD alone, however, arterial hypertension prevalence is similar to that of the general population, and patients with COPD/OSA overlap appear to have the same prevalence rates as patients with OSA alone. Untreated OSA patients are also particularly susceptible to development of atrial fibrillation, as are patients with COPD alone, likely related to nocturnal arterial O₂ desaturation. A community based retrospective cohort analysis, including data collected on 2,873 patients older than 65 years, confirmed an increased risk of new-onset atrial fibrillation in COPD/OSA overlap syndrome compared with OSA or COPD alone.

A high incidence of coronary artery disease, stroke, and heart failure has been reported in epidemiological studies among patients with OSA and COPD alone. However, no such incidence data are available for COPD/OSA overlap. However, Chaouat et al. demonstrated that patients with COPD/OSA overlap syndrome have increased daytime pulmonary vascular resistance compared with patients with OSA alone, whereas Sharma et al. recently documented a higher right ventricular mass and remodelling indices in overlap syndrome compared with patients with COPD alone. In addition, arterial stiffness, a surrogate marker of subclinical atherosclerosis, has also been found to be significantly higher in subjects with COPD/OSA overlap than in those with OSA alone. Finally, whereas increased oxidative stress is associated with both COPD and OSA, with evidence of increased circulating proinflammatory cytokines and leukocytes in both disorders, no specific data exist regarding COPD/OSA overlap syndrome and risk and prevalence of such oxidative stress compared with COPD or OSA alone. Potential key risk factors for endothelial dysfunction, atherosclerosis, and ultimately cardiovascular diseases are depicted in figure 4.
Mortality

In both COPD alone and OSA alone, the risk of excess all-cause mortality increases in association with increasing severity of these disorders. The excess mortality is most marked in younger individuals with OSA and in older patients with COPD. Overall, evidence indicates that mortality is increased in overlap patients. We have recently confirmed this in a large cohort of patients with an average age of 57 years, referred to our sleep laboratory because of suspected SDB. In addition to polygraphy, all patients underwent spirometry as a routine procedure. During a median follow-up period of more than nine years, all-cause mortality was higher in the overlap group untreated for OSA (42.2%) than in the COPD-only group (24.2%) (Fig. 5). In the COPD patients, comorbid untreated OSA remained a risk factor for death even after adjustment for FEV₁ (% predicted) as a surrogate of COPD severity. There were a significantly higher number of cardiovascular deaths in patients with COPD only and untreated overlap syndrome compared with overlap patients treated appropriately for their OSA with CPAP. Interestingly, the second most frequent cause of death was cancer in patients with both OSA and COPD alone.
Nocturnal death risk appears to be increased in COPD compared with the general population, mainly during COPD exacerbations. Nocturnal hypoxaemia, an important pathophysiologic feature of OSA, is associated with sudden cardiac death. Gami et al. reported on 10,701 consecutive adults undergoing diagnostic polysomnography and sought to identify the risk of sudden cardiac death associated with OSA. During an average follow-up of 5.3 years, 142 patients had resuscitated or fatal sudden cardiac death. Sudden cardiac death was best predicted by age older than 60 years, AHI > 20, mean nocturnal SaO2 < 93%, and nadir nocturnal SaO2 < 78%. No data are available in this study regarding the risk of nocturnal death in patients with COPD/OSA overlap versus COPD or OSA alone. Nevertheless, the report by McNicholas and FitzGerald documented that nocturnal death was higher among patients admitted for acute exacerbation of chronic bronchitis or emphysema than in patients admitted for other causes. It is possible that an increased sympathetic activity along with a reduction in the perfusion of oxygen to the myocardium can increase the risk of arrhythmias and mortality during night time hours in COPD patients.

**Treatment**

The management of overlap syndrome should, in general, be based on optimizing treatment for both conditions (COPD and OSA) following corresponding clinical recommendations. There have been no controlled studies on the effect of specific treatments in the management of patients with COPD/OSA studies; no consensus recommendations are available. The goal of such therapy includes improvement in subjective outcomes, such as sleep fragmentation, sleep quality, and daytime sleepiness, as well as optimization of more objective data regarding daytime alertness and function and COPD- and OSA-specific cardiopulmonary outcomes, such as frequency of COPD exacerbation. Correction of hypoxaemia and hypercapnia during sleep is considered especially important to reduce cardiovascular complications and to increase survival.

**Non-invasive ventilation**

Non-invasive ventilation (NIV), currently typically applied as positive airway pressure (PAP) delivery thorough a nasal or face mask, is the most effective treatment for OSA. Continuous PAP (CPAP) is the optimal PAP therapy for most patients with OSA; bi-level PAP, which delivers a higher pressure during inspiration than during expiration, may also be used if a pressure gradient that increases alveolar ventilation is necessary, effective, and tolerated.
For patients with COPD, NIV in a specifically ventilatory mode (usually bi-level PAP) is consistently shown to be highly effective in the setting of acute and acute-on-chronic hypercapnic respiratory insufficiency. In contrast, data regarding the effects of NIV on quality of life, lung function, gas exchange, and long-term survival have been contradictory when it is used in the chronic setting, in part because of the absence of studies of sufficient power and duration. Data have now accrued specific to overlap syndrome regarding nocturnal NIV, specifically CPAP. In the long-term cohort study alluded to above, overlap syndrome patients not treated with CPAP demonstrated both an increased risk of death from any cause and an increased risk of hospitalization for COPD exacerbation compared with overlap patients who were treated with and adhered to CPAP. In another observational study, the use of CPAP added to long-term oxygen therapy improved survival among overlap patients with chronic respiratory failure. Finally, a retrospective analysis of 227 patients with overlap syndrome treated with CPAP revealed that a greater time on CPAP was associated with a reduced risk of death after controlling for common risk factors.

The choice between CPAP and bi-level PAP can be determined during the titration session, based on the pattern of SDB. In cases in which OSA predominates and there is no co-existent consistent sleep-related hypoventilation, CPAP may be most appropriate to treat the OSA component. In cases in which there is evidence of any degree of nocturnal hypoventilation in addition to the apnoeic episodes, bi-level PAP may be more appropriate. Supplemental oxygen should be added to the mask of the PAP circuit if the otherwise optimal-appearing PAP regimen (whether CPAP or bi-level PAP) alone fails to provide satisfactory oxygenation. The ideal setting in which to adjust these parameters is the sleep laboratory, and such “titrations” should be conducted by well-trained technicians with the design, guidance, and interpretation of clinicians with sleep breathing expertise.

**Supplemental oxygen**

In most patients with COPD alone, nocturnal hypoxaemia, when present, is corrected with supplemental O2 through a nasal cannula. Nevertheless, alveolar ventilation of such patients is particularly dependent on the peripheral stimulant effect of hypoxaemia. Therefore, to minimize the tendency toward CO2 retention, particularly during sleep hours, such O2 supplementation should be titrated carefully. The emergence of morning headache after O2 initiation in patients with COPD is an indication to perform a polysomnography study to exclude the coexistence of OSA or to investigate the development of CO2 retention. In OSA, supplemental oxygen treatment without PAP can eliminate or reduce nocturnal hypoxaemia, but it does not reduce the AHI, daytime hyper-somnolence or nocturnal blood pressure. At present it is recommended that nocturnal O2 be used as a complement to NIV in patients with COPD/OSA overlap syndrome.

**Pharmacologic therapy**

The potential use of pharmacological therapy in overlap syndrome can only be extrapolated...
from limited existing data about such treatment in OSA and COPD alone. There is in fact currently no established role for pharmacological treatment of OSA alone, whereas patients with COPD alone receive pharmacological treatment according to current recommendations. The most common drugs currently prescribed in stable COPD, such as long-acting bronchodilators, have been shown to improve nocturnal arterial O₂ saturation but not quality of sleep. Theophylline, potentially useful for patients with COPD and SDB as a central respiratory stimulant with enhancement of the activity of the respiratory muscles, is currently not clearly shown to be efficacious in improving COPD-related SDB or perturbed quality of sleep. Benzodiazepine sleep aids are typically avoided in patients with COPD and with OSA because of concerns that they may decrease the arousal response to hypercapnia, induce hypoventilation, and decrease upper airway muscle tone. There is evidence that non-benzodiazepine hypnotics do not decrease respiratory drive and do not cause daytime drowsiness; however, the indications for and contraindications to any type of sleep aid in these conditions, whether OSA or COPD alone or overlap syndrome, remain to be better established.

CONFLICT OF INTEREST

Sources of support: Instituto Carlos III, Grants #: PI12/02175, PI15/01940.

Unrestrictive grants from Esteve-Teijin & Gasmedic.

No disclaimers to report from the Author concerning the contents of this paper.

REFERENCES


